7 results
To assess uptake of 18F-PD-L1 and 89Zr- nivolumab in tumor lesions.
To assess the anti-tumor activity of LGX818/MEK162 in combination with third targeted agents after progression on LGX818/MEK162 combination therapy.
Safety Lead-inIn patients with BRAF V600E mutant (BRAFV600E) metastatic colorectal cancer (mCRC):Primary: • Assess the safety/tolerability of the combination of encorafenib + binimetinib + cetuximabSecondary:• Assess the activity of encorafenib +…
The main objectives are to understand how clinical markers and biomarkers previously identified in younger and older AD cohorts apply to the extreme elderly (90+ years old) and to identify novel biomarkers linked with resilience to developing…
Primary:* Phase 1b:o Determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of binimetinib administered in combination with nivolumabo Determine the MTD and RP2D of binimetinib administered in combination with nivolumab plus…
The main objectives are to identify markers for amyloid pathology in cognitively normal subjects, to identify risk factors for amyloid pathology in cognitively normal subjects and to identify predictors for cognitive decline in cognitively normal…
The primary objective is to prospectively assess whether a sequential approach with an induction period of 12 weeks with encorafenib + binimetinib followed by an immunotherapy combination with nivolumab + ipilimumab improves Progression Free…